VentrAssist gets TGA approval

By Staff Writers
Monday, 06 August, 2007

Sydney medical device manufacturer Ventracor has received approval from the Therapeutic Goods Administration (TGA) to sell its left ventricular assist device (LVAD) in Australia.

VentrAssist is an implantable blood pump that connects to the left ventricle to assist the diseased heart's pumping function.

It was designed mainly as an alternative to heart transplants.

It has been available previously for advanced heart failure patients participating in clinical trials.

In June, Ventracor achieved a $28.4 million capital raising to increase the number of clinical trial sites in the US for its Bridge to Transplant (BTT) and Destination Therapy (DT) trials.

The BTT trial involves up to 140 patients at heart transplant hospitals in America, with the aiming of evaluating the safety and efficacy of the device in patients whose heart deteriorates before a donor heart becomes available.

The DT protocol is a prospective, randomised, controlled trial. Both trials are being run concurrently.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd